Replies to post #200179 on Innovation Pharmaceuticals Inc (IPIX)

[scottsmith]

Well said. Fact based posts, whether making our IPIX investment look better or worse, are much needed and make this board quite valuable.

[Rdunn88]

Leo's failures the past 5 years...

Over hyping 2014/15, then telegraphing his intentions to up-list, fueling the shorts while never qualifying with improper BOD's in place.

Zero strategy on ABSSSI after proclaiming himself a genius after the Merck/Cubist deal. Still today, there's no direction on ABSSSI.

Waiting a year too late to add more experience. Dr B has been great, but Leo needed to walk away from control back in 2015...

Too many press releases over the years referencing billions, tremendous, partners and so on...

Inability to find major investors or lenders to help move science along... Why couldn't ABSSSI draw interest?

Not fighting Aruda for the gifted shares... Still haunts the company today as K has been a bust.

Too much time worrying about Mako instead of focusing on the task at hand... The Rosen counter lawsuit was never going to win, a waste of shareholder funds.

420K salaries for 3 employees is way too high for a company that's bleeding cash. That's 15 percent of the yearly budget.

P interim? Seems odd to cancel this "with no explanation" after twice projecting it to occur. Which only fuels questions about trial progress.

Launching a 10 patient trail (K) and after 8 months needing an additional site giving no explanation? What's going on here?

BOD additions? Most promising biotechs add meaningful board additions. Who are the current BOD's and what roles do they serve? Are they looking out for the best interests of the shers? Do they have meetings and approve the salary structure?

The stock is where it's at due to poor CEO leadership by not being able to promote the business and find any major investment. Aspire is not shareholder friendly.

The real reasons for this stock trading in-the-toilet is clear-as-day.

[DaubersUP]

I agree with your post. That is why I started discussions this weekend on competition for B-OM. There are many sides to every story and it is truly ignorant to only see one.

I will say; that the company has not responded to me for some time now and that is unusual. I have a feeling they are extremely busy and the tension between all of their CDA's and potential partners have them sitting with a heavy lid on any communication. As Leo has been saying all year. 2017's focus is on partnerships and he knew they would have the phase 2 data sets to achieve that goal.

I recommend everyone look at SOX's sticky post on trial progression. For all the people that post FUD here, that is as clear it can be on how lean and mean this company is. To move along that many trials in 5 years and only add 40-50 million in OS is very respectable.
Note - in 2012 there was zero cash on hand, no financial agreements and the stock price was higher than it was today with the K phase 1 just starting and the only human clinical trial.

GO IPIX